Advertisement
A vs RVTY
Which Stock Would AI Choose? Agilent Technologies (A) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- Both A and RVTY operate in the diagnostics and research segment of healthcare, delivering solutions for life sciences and applied markets.
- Recent market activity shows both stocks reaching or approaching 52-week highs amid earnings beats and raised guidance for fiscal 2026.
- A maintains a larger market capitalization and broader segment exposure compared to RVTY's more focused diagnostics emphasis.
- Relative performance in recent weeks highlights stronger percentage gains for A alongside steady momentum for RVTY driven by reproductive health and immunodiagnostics.
- Sector sentiment remains supportive for both amid broader healthcare capital spending trends, though valuation multiples differ notably between the two.
- Market positioning contrasts include A's scale in cross-lab services versus RVTY's specialized screening platforms.
Introduction
Agilent Technologies (A) and Revvity (RVTY) represent two established players in the diagnostics and research space within the healthcare sector. This comparison examines their business models, recent stock behavior, and relative positioning to assist investors and traders evaluating exposure to life sciences tools, reagents, and diagnostic platforms. Market participants focused on healthcare innovation, earnings momentum, and sector rotation may find the analysis relevant when assessing diversification or tactical allocation within the industry.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides application-focused solutions across life sciences, diagnostics, and applied chemical markets through segments including Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The company serves global customers with instruments, consumables, and services. In recent market activity, shares advanced toward 52-week highs near $160.51, supported by a fiscal second-quarter earnings beat and raised full-year 2026 guidance. Performance reflected double-digit revenue growth and analyst optimism, with the stock exhibiting consistent upward momentum over recent weeks amid positive sector sentiment in healthcare.
Revvity (RVTY) Overview and Recent Performance
Revvity delivers health science solutions spanning discovery to diagnosis, with emphasis on translational multi-omics, imaging, screening, and informatics through Life Sciences and Diagnostics segments. Key offerings include instruments, reagents, and platforms for reproductive health and immunodiagnostics. Recent market activity featured the stock reaching 52-week highs around $124.97 following a second-quarter earnings beat and raised 2026 guidance. Performance benefited from diagnostics segment strength, though life sciences revenue showed modest softness, resulting in steady but comparatively measured gains over recent weeks relative to broader healthcare peers.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the highest-performing AI trading bots suited to prevailing market conditions from a pool of hundreds available. These bots cover thousands of tickers across varied strategies, timeframes, risk profiles, and performance metrics, allowing users to identify those aligned with current trends in volatility, momentum, or sector rotation. Available statistics typically include ranges of historical returns, win rates, and drawdowns that help evaluate suitability without guaranteeing future results. The section offers a professional resource for exploring automated approaches to equities such as those compared here.
Head-to-Head Comparison
Agilent Technologies operates with greater scale and diversified segment exposure, including substantial cross-lab services revenue, while Revvity concentrates more narrowly on diagnostics workflows and reproductive health platforms. Growth drivers differ as A benefits from broad life sciences demand and applied markets, whereas RVTY draws momentum from targeted screening technologies. Recent momentum favored both through earnings outperformance, yet A posted comparatively larger percentage advances amid its larger market capitalization. Risk factors include valuation premiums for RVTY relative to consensus targets and potential cyclicality in life sciences spending for both. Sector exposure remains aligned in healthcare diagnostics, with market sentiment reflecting shared tailwinds from capital expenditure trends but differentiated by company-specific catalysts and stability metrics.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and relative positioning in recent weeks, Tickeron’s AI would currently assign a modest probabilistic edge to A due to its stronger percentage performance, broader segment stability, and alignment with sustained healthcare demand patterns. This assessment remains conditional on continued execution and does not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and RVTY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileRVTY’s FA Score has 3 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- RVTY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- RVTY’s TA Score: 3 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -1.94% price change this week, while RVTY (@Medical Specialties) price change was +1.10% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.68%. For the same industry, the average monthly price growth was +11.00%, and the average quarterly price growth was +34.25%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
RVTY is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Medical Specialties (+5.68% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | RVTY | A / RVTY | |
| Capitalization | 42.5B | 14.5B | 293% |
| EBITDA | 2.04B | 772M | 264% |
| Gain YTD | 11.535 | 34.866 | 33% |
| P/E Ratio | 29.76 | 62.61 | 48% |
| Revenue | 7.37B | 2.91B | 253% |
| Total Cash | 1.76B | 1.02B | 172% |
| Total Debt | 3.95B | 3.34B | 118% |
A | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 95 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 87 | |
PRICE GROWTH RATING 1..100 | 22 | 8 | |
P/E GROWTH RATING 1..100 | 43 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 24 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (11) in the Biotechnology industry is in the same range as RVTY (15) in the Medical Specialties industry. This means that A’s stock grew similarly to RVTY’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RVTY (100) in the Medical Specialties industry. This means that A’s stock grew similarly to RVTY’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for RVTY (87) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than RVTY’s over the last 12 months.
RVTY's Price Growth Rating (8) in the Medical Specialties industry is in the same range as A (22) in the Biotechnology industry. This means that RVTY’s stock grew similarly to A’s over the last 12 months.
RVTY's P/E Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for A (43) in the Biotechnology industry. This means that RVTY’s stock grew somewhat faster than A’s over the last 12 months.
| A | RVTY | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 58% | 4 days ago 86% |
| Stochastic ODDS (%) | 4 days ago 61% | 4 days ago 74% |
| Momentum ODDS (%) | 4 days ago 56% | N/A |
| MACD ODDS (%) | 4 days ago 51% | 4 days ago 63% |
| TrendWeek ODDS (%) | 4 days ago 63% | 4 days ago 67% |
| TrendMonth ODDS (%) | 4 days ago 60% | 4 days ago 64% |
| Advances ODDS (%) | 12 days ago 60% | 12 days ago 65% |
| Declines ODDS (%) | 7 days ago 63% | 4 days ago 67% |
| BollingerBands ODDS (%) | 4 days ago 71% | 4 days ago 65% |
| Aroon ODDS (%) | 4 days ago 64% | 4 days ago 54% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.